A plant for the production of COVID-19 vaccines will appear in Japan
06.02.2023
ТАСС
56 просмотров
The country's first plant for the production of local mRNA vaccines is being built in Japan.
The Japanese pharmaceutical company Daiichi Sankyo has begun construction of Japan's first plant for the production of local mRNA vaccines against the new coronavirus. This was reported by the Nikkei newspaper on Monday.
It is noted that due to the commissioning of the facility, the pharmaceutical company expects to ensure the annual production of about 20 million doses of mRNA vaccines by the 2024 financial year (starting on April 1, 2024). The application for approval of the corresponding drug Daiichi Sankyo, which will reduce Japan's dependence on foreign suppliers, was sent to the Japanese Ministry of Health in January this year.
Moderna, AstraZeneca, and Pfizer, the American companies, as well as the British-Swedish AstraZeneca, use vaccines in Japan. Japanese drugs developed by local pharmaceutical companies have not yet been approved by the country's authorities.
It is noted that due to the commissioning of the facility, the pharmaceutical company expects to ensure the annual production of about 20 million doses of mRNA vaccines by the 2024 financial year (starting on April 1, 2024). The application for approval of the corresponding drug Daiichi Sankyo, which will reduce Japan's dependence on foreign suppliers, was sent to the Japanese Ministry of Health in January this year.
Moderna, AstraZeneca, and Pfizer, the American companies, as well as the British-Swedish AstraZeneca, use vaccines in Japan. Japanese drugs developed by local pharmaceutical companies have not yet been approved by the country's authorities.
Новости партнёров
